Nora Bailey
Psychiatry · Houston, TXNPI 1699191908
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Visioneering Technologies, Inc. at 30.1% of the total. Reporting peaked in 2024 at $1,478 and has fallen 92.9% since, to $105 in 2025.
Across 116 payments — averaging $28.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Visioneering Technologies, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$418
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$198
- Sunovion Pharmaceuticals Inc.$193
- Corium, LLC$192
- Alkermes, Inc.$163
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,27599%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Visioneering Technologies, Inc. | 1 | $1,000 |
| Otsuka America Pharmaceutical, Inc. | 26 | $418 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $198 |
| Sunovion Pharmaceuticals Inc. | 8 | $193 |
| Corium, LLC | 11 | $192 |
| Alkermes, Inc. | 8 | $163 |
| Neos Therapeutics, LP | 9 | $152 |
| Axsome Therapeutics, Inc. | 7 | $143 |
| Supernus Pharmaceuticals, Inc. | 2 | $128 |
| AbbVie | 4 | $105 |
| Bausch Health US, LLC | 5 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $95 |
| Teva Pharmaceuticals USA, Inc. | 5 | $92 |
| Lundbeck LLC | 4 | $80 |
| Johnson & Johnson | 3 | $77 |
| OWP Pharmaceuticals, Inc. | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 2 | $34 |
| Tris Pharma Inc | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 1 | $29 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| C2n Diagnostics, LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$114
How this compares
$3,322 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluoxetine Hcl | 22 | $480 |
| Trazodone Hcl | 13 | $151 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.